Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

J Infect Dis. 2021 Jan 4;223(1):23-27. doi: 10.1093/infdis/jiaa666.

Abstract

We describe a case of chronic coronavirus disease 2019 (COVID-19) in a patient with lymphoma and associated B-cell immunodeficiency. Viral cultures and sequence analysis demonstrate ongoing replication of infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for at least 119 days. The patient had 3 admissions related to COVID-19 over a 4-month period and was treated twice with remdesivir and convalescent plasma with resolution of symptoms. The patient's lack of seroconversion and prolonged course illustrate the importance of humoral immunity in resolving SARS-CoV-2 infection. This case highlights challenges in managing immunocompromised hosts, who may act as persistent shedders and sources of transmission.

Keywords: COVID-19; SARS-CoV-2; antibody; evolution; immunocompromise.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Antibodies, Viral / blood
  • COVID-19 / diagnosis
  • COVID-19 / virology*
  • Hospitalization
  • Humans
  • Immunity, Humoral
  • Immunocompromised Host
  • Lymphoma, Mantle-Cell / complications
  • Male
  • Middle Aged
  • Primary Immunodeficiency Diseases / complications
  • SARS-CoV-2 / physiology*
  • Seroconversion
  • Virus Replication*

Substances

  • Antibodies, Viral
  • remdesivir
  • Adenosine Monophosphate
  • Alanine